Anti-HEL-Human IgG1(D270N)-kappa Isotype control Monoclonal Antibody宿主分子量形式浓度纯化方法储存/保存方法存储溶液
| 概述 | |
| 宿主 |
CHO
|
| 分子量 |
Predicted molecular weight: 146kd
|
| 性能 | |
| 形式 |
liquid
|
| 浓度 |
5-20mg/ml
|
| 纯化方法 |
Protein A affinity column
|
| 储存/保存方法 |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.
|
| 存储溶液 |
PBS, pH 7.4,Contains no stabilizers or preservatives
|
SQ 22536CAS号： 17318-31-9分子式：
C9H11N5O
分子量： 205.22描述纯度储存/保存方法形态别名外观密度熔点沸点折射率IC50PK值Ki 数据可溶性/溶解性MDLPubChem CID靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
SQ 22536 is an A cyclase inhibitor that can permeate the cell. SQ 22536 can block cAMP enhancement mediated by Cordycepin , an inhibitor of human platelet aggregation. In platelet studies SQ 22536 was shown to reverse the antiplatelet effects of Sesamol on p38 MAPK phosphorylation and platelet aggregation, and the stimulatory effects induced by Sesamol on VASP, eNOS phosphorylation, and NO release. SQ 22536 has demonstrated inhibition of the effect of glucagon on rat membrane cyclase activity and has reduced the effect of isoproterenol, epinephrine , norepinephrine, and phenylephrine. |
| 纯度 |
≥98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 形态 |
Solid
|
| 基本信息 | |
| 别名 |
9-THF-Ade； 9-(tetrahydrofuran-2-yl)-9h-purin-6-amine
|
| 外观 |
white to off-white solid
|
| 密度 |
~1.7 g/cm3 (Predicted)
|
| 熔点 |
171.94° C (Predicted)
|
| 沸点 |
~474.8° C at 760 mmHg (Predicted)
|
| 折射率 |
n20D 1.83
|
| IC50 |
PTH-stimulation of adenylate cyclase: IC50 = 200 µM; cAMP production induced by prostaglandin E1: IC50 = 82 µM (platelet lysates); cAMP production induced by prostaglandin E1: IC50 = 1 µM (intact platelets); Adenylyl cyclase: IC50 = 1.4 µM; PI4-kinase alpha subunit: IC50 = 28.2 µM (human)
|
| PK值 |
pKb: 3.82
|
| Ki 数据 |
Adenosine A2b receptor: Ki= 2400 nM (Rattus norvegicus); PI4-kinase type II beta: Ki= 21.2 µM (human); PI4-kinase alpha subunit: Ki= 21.2 µM (human); Adenosine A1 receptor: Ki= 28 µM (Rattus norvegicus); Adenosine A2b receptor: Ki= 23 (Rattus norvegicus)
|
| 可溶性/溶解性 |
DMSO ：41 mg/mL (199.79 mM)
Water ：41 mg/mL (199.79 mM) Ethanol ：41 mg/mL (199.79 mM) |
| MDL |
MFCD00210216
|
| PubChem CID |
5270
|
| 生物活性 | |
| 靶点 |
adenylate cyclase
|
| In vitro(体外研究) |
SQ22536(250 µmol/L) attenuates the inhibitory effect of adenosine against ADP-induced platelet aggregation from 8±5 to 57±5%, respectively (p<0.001). SQ22536 also attenuates an increase of intraplatelet levels of cAMP by adenosine from 29±2 to 9±1 pmol/108 platelets (p<0.05). It has no effect on the platelet antiaggregant activity of inosine (1 to 4 mmol/L) and ADP-induced platelet aggregation.
|
| In vivo(体内研究) |
SQ22536 abolishes the renal protective effects of liraglutide in KK/Ta-Akita mice. the amelioration of glomerular histopathological damage by liraglutide is eliminated in KK/Ta-Akita mice treated with liraglutide in combination with SQ22536. Renal cAMP does not increase after treatment with SQ22536. In a word, the beneficial actions of liraglutide for treatment of nephropathy are inhibited by the adenylate cyclase inhibitor SQ22536.
|
分子结构图
Novus
CJ-42794CAS号： 847728-01-2分子式： C22H17ClFNO4分子量： 413.83描述纯度储存/保存方法别名外观可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
CJ-42794, as a selective antagonist of EP4, less binds to EP2 and does not have binding affinity for EP1 or EP3. It displays minimal effect on numerous other receptors, channels, or enzymes. CJ-42794 delays the healing of gastric ulcers, inhibiting the upregulation of VEGF expression and angiogenesis. EP4, activated by prostaglandin E2 (PGE2), is a G-protein-coupled receptor, which plays vital roles in bone formation and resorption, cancer, and atherosclerosis via elevating the second messenger cyclic AMP (cAMP). |
| 纯度 |
98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 基本信息 | |
| 别名 |
CJ 42794
|
| 外观 |
powder
|
| 可溶性/溶解性 |
DMSO : ≥ 28 mg/mL (67.66 mM)
|
| 生物活性 | |
| 靶点 |
EP2；EP4
|
| In vitro(体外研究) |
CJ-42794 exhibited remarkable binding activity to EP4 and suppressed PGE2-triggered elevations of intracellular cAMP levels in a concentration-dependent fashion in HEK293 cells overexpressing human EP4. Moreover, CJ-42794, concentration-dependently, reversed the inhibitory effects of PGE2 on lipopolysaccharide-evoked tumor necrosis factor α production, which suggested that CJ-42794 had excellent pharmacological properties used for exploring the physiological role of EP4 .
|
| In vivo(体内研究) |
Male Sprague-Dawley rats and C57BL/6 mice were given subcutaneously 3 and 10 mg/kg for rats, 10 mg/kg for mice once daily for 7 or 14 days. Compared to the controls, CJ-42794, in a dose-dependent manner, impaired and delayed the gastric ulcer healing in rats and mice. CJ-42794 markedly dampened the increase of VEGF expression in ulcerated mucosa of the mouse stomach and the primary gastric fibroblasts of rat.
|
分子结构图
Human CD24 MDA-MB-231 Cell Line描述来源应用浓度使用方法储存/保存方法形态外观靶点
| 产品描述 | |
| 描述 |
细胞类型：MDA-MB-231;
载体类型：PLVX |
| 来源 |
Human
|
| 应用 |
免疫；抗体筛选；体外功能研究
|
| 浓度 |
5E6 cells/vial
|
| 使用方法 |
复苏后培养
|
| 储存/保存方法 |
Liquid nitrogen. 细胞冻存：90% Medium+10% DMSO
|
| 形态 |
液体冻存
|
| 基本信息 | |
| 外观 |
淡黄色
|
| 生物活性 | |
| 靶点 |
CD24
|
Tocris
| 货号 | 产品名称 | 包装 | 品牌 |
| 1345-50MG | AF-DX 384 | 50 mg | Tocris |
| 1346-1MG | des-Gln14-Ghrelin (rat) | 1 mg | Tocris |
| 1347-10MG | Nafadotride | 10 mg | Tocris |
| 1347-50MG | Nafadotride | 50 mg | Tocris |
| 1348-10MG | UB 165 fumarate | 10 mg | Tocris |
| 1349-10MG | (R)-(-)-Rolipram | 10 mg | Tocris |
| 1349-50MG | (R)-(-)-Rolipram | 50 mg | Tocris |
| 1350-10MG | (S)-(+)-Rolipram | 10 mg | Tocris |
| 1350-50MG | (S)-(+)-Rolipram | 50 mg | Tocris |
| 1352-500UG | Phospho-Glycogen Synthase Peptide-2 (substrate) | 500 ug | Tocris |
| 1353-1MG | Akt/SKG Substrate Peptide | 1 mg | Tocris |
| 1354-5MG | Arvanil | 5 mg | Tocris |
| 1354-25MG | Arvanil | 25 mg | Tocris |
| 1355-10MG | P1075 | 10 mg | Tocris |
| 1355-50MG | P1075 | 50 mg | Tocris |
| 1356-10MG | MG 624 | 10 mg | Tocris |
| 1356-50MG | MG 624 | 50 mg | Tocris |
| 1357-10MG | U 99194 maleate | 10 mg | Tocris |
| 1357-50MG | U 99194 maleate | 50 mg | Tocris |
| 1358-1MG | Nociceptin (1-13)NH2 | 1 mg | Tocris |
| 1359-10MG | VUF 5574 | 10 mg | Tocris |
| 1359-50MG | VUF 5574 | 50 mg | Tocris |
| 1361-10MG | PD 123319 ditrifluoroacetate | 10 mg | Tocris |
| 1361-50MG | PD 123319 ditrifluoroacetate | 50 mg | Tocris |
| 1362-1MG | 5′-Iodoresiniferatoxin | 1 mg | Tocris |
| 1363-10MG | PD 81723 | 10 mg | Tocris |
| 1363-50MG | PD 81723 | 50 mg | Tocris |
| 1364-1G | Colchicine | 1 g | Tocris |
| 1365-1MG | [cPP1-7,NPY19-23,Ala31,Aib32,Gln34] – hPancreatic Polypeptide | 1 mg | Tocris |
| 1366-10MG | ZM 449829 | 10 mg | Tocris |
| 1366-50MG | ZM 449829 | 50 mg | Tocris |
| 1367-10MG | ZM 39923 hydrochloride | 10 mg | Tocris |
| 1367-50MG | ZM 39923 hydrochloride | 50 mg | Tocris |
| 1368-1MG | Geldanamycin | 1 mg | Tocris |
| 1369-10MG | UBP1112 | 10 mg | Tocris |
| 1369-50MG | UBP1112 | 50 mg | Tocris |
| 1370-1MG | Sphingosine-1-phosphate | 1 mg | Tocris |
| 1371-10MG | SB 200646 hydrochloride | 10 mg | Tocris |
| 1371-50MG | SB 200646 hydrochloride | 50 mg | Tocris |
| 1372-10MG | SB 204741 | 10 mg | Tocris |
| 1372-50MG | SB 204741 | 50 mg | Tocris |
| 1375-10MG | SB 228357 | 10 mg | Tocris |
| 1375-50MG | SB 228357 | 50 mg | Tocris |
| 1376-10MG | SB 218795 | 10 mg | Tocris |
| 1376-50MG | SB 218795 | 50 mg | Tocris |
| 1377-10MG | Cromakalim | 10 mg | Tocris |
| 1377-50MG | Cromakalim | 50 mg | Tocris |
| 1378-10MG | Levcromakalim | 10 mg | Tocris |
| 1378-50MG | Levcromakalim | 50 mg | Tocris |
| 1379-10MG | SB 221284 | 10 mg | Tocris |
| 1379-50MG | SB 221284 | 50 mg | Tocris |
| 1380-10MG | PMPA (NAALADase inhibitor) | 10 mg | Tocris |
| 1380-50MG | PMPA (NAALADase inhibitor) | 50 mg | Tocris |
| 1381-10MG | GW 5074 | 10 mg | Tocris |
| 1381-50MG | GW 5074 | 50 mg | Tocris |
| 1382-10MG | L-152,804 | 10 mg | Tocris |
| 1382-50MG | L-152,804 | 50 mg | Tocris |
| 1383-10MG | BML-190 | 10 mg | Tocris |
| 1383-50MG | BML-190 | 50 mg | Tocris |
| 1384-10MG | McN-A 343 | 10 mg | Tocris |
| 1384-50MG | McN-A 343 | 50 mg | Tocris |
| 1385-10MG | MRS 1334 | 10 mg | Tocris |
| 1385-50MG | MRS 1334 | 50 mg | Tocris |
| 1386-1MG | [Ala11,22,28]VIP | 1 mg | Tocris |
| 1387-1MG | Ac-RYYRWK-NH2 | 1 mg | Tocris |
| 1390-10MG | (-)-Cytisine | 10 mg | Tocris |
| 1390-50MG | (-)-Cytisine | 50 mg | Tocris |
| 1391-10MG | NF 449 | 10 mg | Tocris |
| 1391-50MG | NF 449 | 50 mg | Tocris |
| 1392-5MG | VDM 11 | 5 mg | Tocris |
| 1392-25MG | VDM 11 | 25 mg | Tocris |
| 1393-10MG | SB 222200 | 10 mg | Tocris |
| 1393-50MG | SB 222200 | 50 mg | Tocris |
| 1394-10MG | (RS)-3,4-DCPG | 10 mg | Tocris |
| 1394-50MG | (RS)-3,4-DCPG | 50 mg | Tocris |
| 1395-10MG | (R)-3,4-DCPG | 10 mg | Tocris |
| 1395-50MG | (R)-3,4-DCPG | 50 mg | Tocris |
| 1396-10MG | Fenretinide | 10 mg | Tocris |
| 1396-50MG | Fenretinide | 50 mg | Tocris |
| 1397-10MG | PP 1 | 10 mg | Tocris |
| 1398-10MG | Kenpaullone | 10 mg | Tocris |
| 1399-10MG | CP 339818 hydrochloride | 10 mg | Tocris |
| 1399-50MG | CP 339818 hydrochloride | 50 mg | Tocris |
| 1400-10MG | SCH 202676 hydrobromide | 10 mg | Tocris |
| 1400-50MG | SCH 202676 hydrobromide | 50 mg | Tocris |
| 1401-10MG | NU 1025 | 10 mg | Tocris |
| 1401-50MG | NU 1025 | 50 mg | Tocris |
| 1402-10MG | SB 203580 hydrochloride | 10 mg | Tocris |
| 1403-10MG | FPL 64176 | 10 mg | Tocris |
| 1403-50MG | FPL 64176 | 50 mg | Tocris |
| 1405-10MG | (-)-Terreic acid | 10 mg | Tocris |
| 1406-1MG | Trichostatin A | 1 mg | Tocris |
| 1407-10MG | PP 2 | 10 mg | Tocris |
| 1408-10MG | YM 022 | 10 mg | Tocris |
| 1408-50MG | YM 022 | 50 mg | Tocris |
| 1409-10MG | CGP 39551 | 10 mg | Tocris |
| 1409-50MG | CGP 39551 | 50 mg | Tocris |
| 1410-10MG | SDM25N hydrochloride | 10 mg | Tocris |
| 1410-50MG | SDM25N hydrochloride | 50 mg | Tocris |
| 1411-5MG | Noladin ether | 5 mg | Tocris |
| 1411-25MG | Noladin ether | 25 mg | Tocris |
| 1412-10MG | Chromanol 293B | 10 mg | Tocris |
| 1412-50MG | Chromanol 293B | 50 mg | Tocris |
| 1413-10MG | NAS-181 | 10 mg | Tocris |
| 1413-50MG | NAS-181 | 50 mg | Tocris |
| 1414-1G | Scopolamine hydrobromide | 1 g | Tocris |
| 1415-10MG | 1400W dihydrochloride | 10 mg | Tocris |
| 1415-50MG | 1400W dihydrochloride | 50 mg | Tocris |
| 1416-10MG | Homoharringtonine | 10 mg | Tocris |
| 1417-50MG | Daidzein | 50 mg | Tocris |
| 1418-100MG | Resveratrol | 100 mg | Tocris |
| 1419-10MG | Naloxone benzoylhydrazone | 10 mg | Tocris |
| 1419-50MG | Naloxone benzoylhydrazone | 50 mg | Tocris |
| 1420-100UG | D-myo-Inositol-1,3,4,5-tetrakisphosphate, octapotassium salt | 100 ug | Tocris |
| 1421-5MG | MAFP | 5 mg | Tocris |
| 1422-10MG | DCEBIO | 10 mg | Tocris |
| 1422-50MG | DCEBIO | 50 mg | Tocris |
| 1425-10MG | (S)-(+)-Dimethindene maleate | 10 mg | Tocris |
| 1425-50MG | (S)-(+)-Dimethindene maleate | 50 mg | Tocris |
| 1426-10MG | PPT | 10 mg | Tocris |
| 1426-50MG | PPT | 50 mg | Tocris |
| 1427-10MG | Citalopram hydrobromide | 10 mg | Tocris |
| 1427-50MG | Citalopram hydrobromide | 50 mg | Tocris |
| 1428-100UG | Amyloid β-Peptide (1-42) (human) | 100 ug | Tocris |
| 1429-1MG | Amyloid β-peptide (25-35) (human) | 1 mg | Tocris |
| 1430-10MG | DuP 697 | 10 mg | Tocris |
| 1430-50MG | DuP 697 | 50 mg | Tocris |
| 1431-1MG | DPDPE | 1 mg | Tocris |
| 1435-10MG | SQ 22536 | 10 mg | Tocris |
| 1435-50MG | SQ 22536 | 50 mg | Tocris |
| 1436-10MG | MDL 12330A hydrochloride | 10 mg | Tocris |
| 1436-50MG | MDL 12330A hydrochloride | 50 mg | Tocris |
| 1437-10MG | D609 | 10 mg | Tocris |
| 1437-50MG | D609 | 50 mg | Tocris |
| 1439-100MG | Ruthenium Red | 100 mg | Tocris |
| 1440-10MG | BMY 14802 hydrochloride | 10 mg | Tocris |
| 1440-50MG | BMY 14802 hydrochloride | 50 mg | Tocris |
| 1441-10MG | BMS 182874 hydrochloride | 10 mg | Tocris |
| 1441-50MG | BMS 182874 hydrochloride | 50 mg | Tocris |
| 1442-10MG | BMY 45778 | 10 mg | Tocris |
| 1442-50MG | BMY 45778 | 50 mg | Tocris |
| 1443-100UG | Metastin (human) | 100 ug | Tocris |
| 1445-5MG | N-Arachidonylglycine | 5 mg | Tocris |
| 1445-25MG | N-Arachidonylglycine | 25 mg | Tocris |
| 1446-5MG | O-2093 | 5 mg | Tocris |
| 1446-25MG | O-2093 | 25 mg | Tocris |
| 1447-10MG | SKF 81297 hydrobromide | 10 mg | Tocris |
| 1447-50MG | SKF 81297 hydrobromide | 50 mg | Tocris |
| 1448-10MG | Formoterol hemifumarate | 10 mg | Tocris |
| 1448-50MG | Formoterol hemifumarate | 50 mg | Tocris |
| 1450-1MG | Galanin (1-15) (porcine, rat) | 1 mg | Tocris |
| 1451-1MG | Galanin (2-29) (rat) | 1 mg | Tocris |
| 1453-100MG | Clemastine fumarate | 100 mg | Tocris |
| 1454-10MG | GYKI 52466 dihydrochloride | 10 mg | Tocris |
| 1454-50MG | GYKI 52466 dihydrochloride | 50 mg | Tocris |
| 1455-500UG | Orexin A (human, rat, mouse) | 500 ug | Tocris |
| 1456-500UG | Orexin B (human) | 500 ug | Tocris |
| 1457-500UG | Orexin B (mouse) | 500 ug | Tocris |
| 1458-1MG | DAPK Substrate Peptide | 1 mg | Tocris |
| 1459-10MG | SU 4312 | 10 mg | Tocris |
| 1460-10MG | PACOCF3 | 10 mg | Tocris |
| 1461-10MG | Linomide | 10 mg | Tocris |
| 1461-50MG | Linomide | 50 mg | Tocris |
| 1462-5MG | AACOCF3 | 5 mg | Tocris |
| 1462-25MG | AACOCF3 | 25 mg | Tocris |
| 1463-1MG | Ghrelin (human) | 1 mg | Tocris |
| 1464-1MG | TFLLR-NH2 | 1 mg | Tocris |
| 1465-1MG | Ghrelin (rat) | 1 mg | Tocris |
| 1466-1MG | PPAHV | 1 mg | Tocris |
| 1467-10MG | Daunorubicin hydrochloride | 10 mg | Tocris |
| 1468-1MG | SLIGRL-NH2 | 1 mg | Tocris |
| 1469-10MG | CGP 37849 | 10 mg | Tocris |
| 1469-50MG | CGP 37849 | 50 mg | Tocris |
| 1470-10MG | Flecainide acetate | 10 mg | Tocris |
| 1470-50MG | Flecainide acetate | 50 mg | Tocris |
| 1471-10MG | Etomidate | 10 mg | Tocris |
| 1471-50MG | Etomidate | 50 mg | Tocris |
| 1472-100MG | Suramin hexasodium salt | 100 mg | Tocris |
| 1475-10MG | (-)-[3R,4S]-Chromanol 293B | 10 mg | Tocris |
| 1475-50MG | (-)-[3R,4S]-Chromanol 293B | 50 mg | Tocris |
| 1476-1MG | Gap 27 | 1 mg | Tocris |
| 1477-10MG | GR 127935 hydrochloride | 10 mg | Tocris |
| 1477-50MG | GR 127935 hydrochloride | 50 mg | Tocris |
| 1479-100MG | Mifepristone | 100 mg | Tocris |
| 1480-10MG | FIT | 10 mg | Tocris |
| 1480-50MG | FIT | 50 mg | Tocris |
| 1481-10MG | (-)-5′-DMH-CBD | 10 mg | Tocris |
| 1482-1MG | D-myo-Inositol 1,4,5-trisphosphate, hexapotassium salt | 1 mg | Tocris |
| 1483-10MG | GR 89696 fumarate | 10 mg | Tocris |
| 1483-50MG | GR 89696 fumarate | 50 mg | Tocris |
| 1484-10MG | Oleylethanolamide | 10 mg | Tocris |
| 1484-50MG | Oleylethanolamide | 50 mg | Tocris |
| 1485-5MG | DEA | 5 mg | Tocris |
| 1485-25MG | DEA | 25 mg | Tocris |
| 1486-500UG | GR 231118 | 500 ug | Tocris |
| 1487-1MG | AY-NH2 | 1 mg | Tocris |
| 1488-1MG | tcY-NH2 | 1 mg | Tocris |
| 1489-1MG | Mithramycin A | 1 mg | Tocris |
| 1490-10MG | MNI-caged-L-glutamate | 10 mg | Tocris |
| 1490-50MG | MNI-caged-L-glutamate | 50 mg | Tocris |
| 1493-10MG | CGP 78608 hydrochloride | 10 mg | Tocris |
| 1493-50MG | CGP 78608 hydrochloride | 50 mg | Tocris |
| 1494-10MG | DPN | 10 mg | Tocris |
| 1494-50MG | DPN | 50 mg | Tocris |
| 1495-10MG | Combretastatin A4 | 10 mg | Tocris |
| 1495-50MG | Combretastatin A4 | 50 mg | Tocris |
| 1496-10MG | SP 600125 | 10 mg | Tocris |
| 1496-50MG | SP 600125 | 50 mg | Tocris |
| 1497-10MG | Rimcazole dihydrochloride | 10 mg | Tocris |
| 1497-50MG | Rimcazole dihydrochloride | 50 mg | Tocris |
| 1499-10MG | CL 316243 disodium salt | 10 mg | Tocris |
| 1499-50MG | CL 316243 disodium salt | 50 mg | Tocris |
| 1500-1MG | BQ 788 sodium salt | 1 mg | Tocris |
| 1504-10MG | Milrinone | 10 mg | Tocris |
| 1504-50MG | Milrinone | 50 mg | Tocris |
| 1505-100MG | Mycophenolic acid | 100 mg | Tocris |
| 1506-50MG | Terazosin hydrochloride | 50 mg | Tocris |
| 1507-10MG | FR 122047 hydrochloride | 10 mg | Tocris |
| 1507-50MG | FR 122047 hydrochloride | 50 mg | Tocris |
| 1508-10MG | GW 9662 | 10 mg | Tocris |
| 1508-50MG | GW 9662 | 50 mg | Tocris |
| 1509-10MG | TMS | 10 mg | Tocris |
| 1509-50MG | TMS | 50 mg | Tocris |
| 1510-10MG | Ozagrel hydrochloride | 10 mg | Tocris |
| 1510-50MG | Ozagrel hydrochloride | 50 mg | Tocris |
| 1511-10MG | SR 59230A hydrochloride | 10 mg | Tocris |
| 1511-50MG | SR 59230A hydrochloride | 50 mg | Tocris |
| 1512-10MG | SB 205384 | 10 mg | Tocris |
| 1512-50MG | SB 205384 | 50 mg | Tocris |
| 1513-10MG | CGP 7930 | 10 mg | Tocris |
| 1513-50MG | CGP 7930 | 50 mg | Tocris |
| 1514-10MG | CGP 13501 | 10 mg | Tocris |
| 1514-50MG | CGP 13501 | 50 mg | Tocris |
| 1515-1MG | 17-AAG | 1 mg | Tocris |
| 1516-10MG | SDZ 21009 | 10 mg | Tocris |
| 1516-50MG | SDZ 21009 | 50 mg | Tocris |
| 1518-10MG | 5-Iodo-A-85380 dihydrochloride | 10 mg | Tocris |
| 1519-10MG | Quinelorane hydrochloride | 10 mg | Tocris |
| 1520-1MG | Hypericin | 1 mg | Tocris |
| 1521-1MG | LY 233053 | 1 mg | Tocris |
| 1521-10MG | LY 233053 | 10 mg | Tocris |
| 1521-50MG | LY 233053 | 50 mg | Tocris |
| 1523-10MG | LY 215840 | 10 mg | Tocris |
| 1523-50MG | LY 215840 | 50 mg | Tocris |
| 1524-10MG | LY 288513 | 10 mg | Tocris |
| 1524-50MG | LY 288513 | 50 mg | Tocris |
| 1526-10MG | Mevastatin | 10 mg | Tocris |
| 1526-50MG | Mevastatin | 50 mg | Tocris |
| 1527-200UG | 5-Iodo-A-85380, 5-trimethylstannyl N-BOC derivative | 200 ug | Tocris |
| 1529-10MG | SNC 162 | 10 mg | Tocris |
| 1529-50MG | SNC 162 | 50 mg | Tocris |
| 1530-10MG | Lovastatin | 10 mg | Tocris |
| 1530-50MG | Lovastatin | 50 mg | Tocris |
| 1531-10MG | Icilin | 10 mg | Tocris |
| 1531-50MG | Icilin | 50 mg | Tocris |
| 1534-10MG | A 68930 hydrochloride | 10 mg | Tocris |
| 1534-50MG | A 68930 hydrochloride | 50 mg | Tocris |
| 1535-1MG | Hemokinin 1 (mouse) | 1 mg | Tocris |
| 1539-1MG | β-Pompilidotoxin | 1 mg | Tocris |
| 1540-10MG | DCPIB | 10 mg | Tocris |
| 1540-50MG | DCPIB | 50 mg | Tocris |
| 1541-10MG | HA14-1 | 10 mg | Tocris |
| 1541-50MG | HA14-1 | 50 mg | Tocris |
| 1542-10MG | Splitomicin | 10 mg | Tocris |
| 1542-50MG | Splitomicin | 50 mg | Tocris |
| 1543-10MG | (S)-CPW 399 | 10 mg | Tocris |
| 1543-50MG | (S)-CPW 399 | 50 mg | Tocris |
| 1544-10MG | (±)-Bay K 8644 | 10 mg | Tocris |
| 1544-50MG | (±)-Bay K 8644 | 50 mg | Tocris |
| 1545-10MG | (R)-(+)-Bay K 8644 | 10 mg | Tocris |
| 1545-50MG | (R)-(+)-Bay K 8644 | 50 mg | Tocris |
| 1546-10MG | (S)-(-)-Bay K 8644 | 10 mg | Tocris |
| 1546-50MG | (S)-(-)-Bay K 8644 | 50 mg | Tocris |
| 1547-10MG | NSC 95397 | 10 mg | Tocris |
| 1547-50MG | NSC 95397 | 50 mg | Tocris |
| 1548-50MG | Cantharidin | 50 mg | Tocris |
| 1549-10MG | CD 437 | 10 mg | Tocris |
| 1549-50MG | CD 437 | 50 mg | Tocris |
| 1550-10MG | SC 560 | 10 mg | Tocris |
| 1551-1MG | STO-609 acetate | 1 mg | Tocris |
| 1551-10MG | STO-609 acetate | 10 mg | Tocris |
| 1551-50MG | STO-609 acetate | 50 mg | Tocris |
| 1552-1MG | UFP-101 | 1 mg | Tocris |
| 1554-10MG | Piceatannol | 10 mg | Tocris |
| 1555-10MG | AG 825 | 10 mg | Tocris |
| 1555-50MG | AG 825 | 50 mg | Tocris |
| 1556-1MG | 6′-Iodoresiniferatoxin | 1 mg | Tocris |
| 1558-10MG | Tracazolate hydrochloride | 10 mg | Tocris |
| 1558-50MG | Tracazolate hydrochloride | 50 mg | Tocris |
| 1559-10MG | Roxindole hydrochloride | 10 mg | Tocris |
| 1559-50MG | Roxindole hydrochloride | 50 mg | Tocris |
| 1560-1MG | CTAP | 1 mg | Tocris |
| 1561-10MG | (S)-SNAP 5114 | 10 mg | Tocris |
| 1561-50MG | (S)-SNAP 5114 | 50 mg | Tocris |
| 1562-1MG | Angiotensin (1-7) | 1 mg | Tocris |
| 1563-1MG | Angiotensin I (human, mouse, rat) | 1 mg | Tocris |
| 1564-1MG | Angiotensin III (human, mouse) | 1 mg | Tocris |
| 1565-1MG | JIP-1 (153-163) | 1 mg | Tocris |
| 1566-1MG | [(pF)Phe4]Nociceptin(1-13)NH2 | 1 mg | Tocris |
| 1567-1MG | Thiolutin | 1 mg | Tocris |
| 1568-5MG | NADA | 5 mg | Tocris |
| 1568-25MG | NADA | 25 mg | Tocris |
| 1569-5MG | Virodhamine | 5 mg | Tocris |
| 1569-25MG | Virodhamine | 25 mg | Tocris |
| 1570-10MG | (-)-Cannabidiol | 10 mg | Tocris |
| 1570-50MG | (-)-Cannabidiol | 50 mg | Tocris |
| 1571-1MG | Cucurbitacin I | 1 mg | Tocris |
| 1572-5MG | Ac-YVAD-AFC | 5 mg | Tocris |
| 1575-5MG | Ac-LEHD-AFC | 5 mg | Tocris |
| 1576-5MG | Ac-IEPD-AFC | 5 mg | Tocris |
| 1577-1MG | L-R4W2 | 1 mg | Tocris |
| 1578-1MG | CTOP | 1 mg | Tocris |
| 1579-10MG | HEMADO | 10 mg | Tocris |
| 1579-50MG | HEMADO | 50 mg | Tocris |
| 1580-10MG | Purvalanol A | 10 mg | Tocris |
| 1580-50MG | Purvalanol A | 50 mg | Tocris |
| 1581-10MG | Purvalanol B | 10 mg | Tocris |
| 1581-50MG | Purvalanol B | 50 mg | Tocris |
| 1582-1MG | Neurokinin B (human, porcine) | 1 mg | Tocris |
| 1584-10MG | MRS 1706 | 10 mg | Tocris |
| 1584-50MG | MRS 1706 | 50 mg | Tocris |
| 1586-10MG | SKF 83566 hydrobromide | 10 mg | Tocris |
| 1586-50MG | SKF 83566 hydrobromide | 50 mg | Tocris |
| 1587-1MG | Ro 32-0432 hydrochloride | 1 mg | Tocris |
| 1588-10MG | Indatraline hydrochloride | 10 mg | Tocris |
| 1588-50MG | Indatraline hydrochloride | 50 mg | Tocris |
| 1589-1MG | Radicicol | 1 mg | Tocris |
| 1590-1MG | [Arg14,Lys15]Nociceptin | 1 mg | Tocris |
| 1591-10MG | NBI 27914 hydrochloride | 10 mg | Tocris |
| 1591-50MG | NBI 27914 hydrochloride | 50 mg | Tocris |
| 1592-10MG | SCH 79797 dihydrochloride | 10 mg | Tocris |
| 1592-50MG | SCH 79797 dihydrochloride | 50 mg | Tocris |
| 1594-1MG | Ro 25-6981 maleate | 1 mg | Tocris |
| 1594-10MG | Ro 25-6981 maleate | 10 mg | Tocris |
| 1594-50MG | Ro 25-6981 maleate | 50 mg | Tocris |
| 1595-2MG | pep2m | 2 mg | Tocris |
| 1596-2MG | pep4c | 2 mg | Tocris |
| 1597-2MG | pep2-SVKI | 2 mg | Tocris |
| 1598-2MG | pep2-SVKE | 2 mg | Tocris |
| 1599-2MG | pep2-EVKI | 2 mg | Tocris |
| 1600-2MG | pep2-AVKI | 2 mg | Tocris |
| 1601-2MG | Pep1-TGL | 2 mg | Tocris |
| 1602-2MG | Pep1-AGL | 2 mg | Tocris |
| 1603-10MG | NKH 477 | 10 mg | Tocris |
| 1603-50MG | NKH 477 | 50 mg | Tocris |
| 1604-1MG | Urocortin (human) | 1 mg | Tocris |
| 1605-1MG | Urocortin (rat) | 1 mg | Tocris |
| 1606-500UG | Astressin | 500 ug | Tocris |
| 1607-1MG | CRF (6-33) | 1 mg | Tocris |
| 1608-500UG | Stressin I | 500 ug | Tocris |
| 1609-500UG | Sauvagine | 500 ug | Tocris |
| 1610-10MG | Rottlerin | 10 mg | Tocris |
| 1610-50MG | Rottlerin | 50 mg | Tocris |
| 1611-10MG | Lamotrigine | 10 mg | Tocris |
| 1611-50MG | Lamotrigine | 50 mg | Tocris |
| 1612-10MG | SB 269970 hydrochloride | 10 mg | Tocris |
| 1612-50MG | SB 269970 hydrochloride | 50 mg | Tocris |
| 1614-1MG | SB 431542 | 1 mg | Tocris |
| 1614-10MG | SB 431542 | 10 mg | Tocris |
| 1615-10MG | SB 366791 | 10 mg | Tocris |
| 1615-50MG | SB 366791 | 50 mg | Tocris |
| 1616-1MG | SB 216763 | 1 mg | Tocris |
| 1616-10MG | SB 216763 | 10 mg | Tocris |
| 1616-50MG | SB 216763 | 50 mg | Tocris |
| 1617-10MG | SB 415286 | 10 mg | Tocris |
| 1617-50MG | SB 415286 | 50 mg | Tocris |
| 1618-500UG | Peptide YY (3-36) | 500 ug | Tocris |
| 1619-1MG | [Orn8]-Urotensin II | 1 mg | Tocris |
| 1620-10MG | Alprostadil | 10 mg | Tocris |
| 1620-50MG | Alprostadil | 50 mg | Tocris |
| 1621-100MG | Streptozocin | 100 mg | Tocris |
| 1621-500MG | Streptozocin | 500 mg | Tocris |
| 1622-10MG | Remacemide hydrochloride | 10 mg | Tocris |
| 1622-50MG | Remacemide hydrochloride | 50 mg | Tocris |
| 1623-1MG | Cyclopamine | 1 mg | Tocris |
| 1624-10MG | 2-Methylthioadenosine diphosphate trisodium salt | 10 mg | Tocris |
| 1625-10MG | DFB | 10 mg | Tocris |
| 1625-50MG | DFB | 50 mg | Tocris |
| 1626-100UG | Calphostin C | 100 ug | Tocris |
| 1629-100UG | Herbimycin A | 100 ug | Tocris |
| 1632-1MG | MEN 10376 | 1 mg | Tocris |
| 1633-1MG | MEN 10627 | 1 mg | Tocris |
| 1634-10MG | Y-29794 oxalate | 10 mg | Tocris |
| 1634-50MG | Y-29794 oxalate | 50 mg | Tocris |
| 1635-10MG | RP 67580 | 10 mg | Tocris |
| 1635-50MG | RP 67580 | 50 mg | Tocris |
| 1636-10MG | IEM 1460 | 10 mg | Tocris |
| 1636-50MG | IEM 1460 | 50 mg | Tocris |
| 1637-10MG | Argatroban | 10 mg | Tocris |
| 1637-50MG | Argatroban | 50 mg | Tocris |
| 1638-10MG | U 18666A | 10 mg | Tocris |
| 1639-10MG | AY 9944 dihydrochloride | 10 mg | Tocris |
| 1640-1MG | [bAla8]-Neurokinin A(4-10) | 1 mg | Tocris |
| 1641-5MG | OLDA | 5 mg | Tocris |
| 1641-25MG | OLDA | 25 mg | Tocris |
| 1642-1MG | Urotensin II (human) | 1 mg | Tocris |
| 1643-10MG | D-64131 | 10 mg | Tocris |
| 1643-50MG | D-64131 | 50 mg | Tocris |
| 1644-10MG | Mesulergine hydrochloride | 10 mg | Tocris |
| 1644-50MG | Mesulergine hydrochloride | 50 mg | Tocris |
| 1645-1MG | 8CPT-2Me-cAMP, sodium salt | 1 mg | Tocris |
| 1646-10MG | Lonidamine | 10 mg | Tocris |
| 1646-50MG | Lonidamine | 50 mg | Tocris |
| 1650-1MG | BAM 22P | 1 mg | Tocris |
| 1652-1MG | Apamin | 1 mg | Tocris |
| 1655-10MG | O-2050 | 10 mg | Tocris |
| 1657-10MG | Ginkgolide B | 10 mg | Tocris |
| 1657-50MG | Ginkgolide B | 50 mg | Tocris |
| 1658-10MG | GR 125487 sulfamate | 10 mg | Tocris |
| 1658-50MG | GR 125487 sulfamate | 50 mg | Tocris |
| 1659-10MG | Fenoldopam hydrochloride | 10 mg | Tocris |
| 1659-50MG | Fenoldopam hydrochloride | 50 mg | Tocris |
| 1660-10MG | Salmeterol | 10 mg | Tocris |
| 1660-50MG | Salmeterol | 50 mg | Tocris |
| 1661-10MG | SB 206553 hydrochloride | 10 mg | Tocris |
| 1661-50MG | SB 206553 hydrochloride | 50 mg | Tocris |
| 1662-10MG | SKF 77434 hydrobromide | 10 mg | Tocris |
| 1662-50MG | SKF 77434 hydrobromide | 50 mg | Tocris |
| 1663-10MG | BW 373U86 | 10 mg | Tocris |
| 1664-10MG | GW 1929 hydrochloride | 10 mg | Tocris |
| 1664-50MG | GW 1929 hydrochloride | 50 mg | Tocris |
| 1667-1MG | GR 94800 | 1 mg | Tocris |
| 1668-1MG | GR 64349 | 1 mg | Tocris |
| 1669-1MG | GR 73632 | 1 mg | Tocris |
| 1670-1MG | GR 82334 | 1 mg | Tocris |
| 1671-10MG | PD 102807 | 10 mg | Tocris |
| 1671-50MG | PD 102807 | 50 mg | Tocris |
| 1672-10MG | RU 28318, potassium salt | 10 mg | Tocris |
| 1672-50MG | RU 28318, potassium salt | 50 mg | Tocris |
| 1673-10MG | Cl-HIBO | 10 mg | Tocris |
| 1673-50MG | Cl-HIBO | 50 mg | Tocris |
| 1674-10MG | LE 300 | 10 mg | Tocris |
| 1674-50MG | LE 300 | 50 mg | Tocris |
| 1675-10MG | YM 90709 | 10 mg | Tocris |
| 1676-10MG | T 0156 hydrochloride | 10 mg | Tocris |
| 1676-50MG | T 0156 hydrochloride | 50 mg | Tocris |
| 1677-10MG | GW 7647 | 10 mg | Tocris |
| 1677-50MG | GW 7647 | 50 mg | Tocris |
| 1682-10MG | PIT | 10 mg | Tocris |
| 1682-50MG | PIT | 50 mg | Tocris |
| 1683-200UG | K 252a | 200 ug | Tocris |
| 1684-1ML | Tocrisolve™ 100 | 1 ml | Tocris |
| 1684-10ML | Tocrisolve™ 100 | 10 ml | Tocris |
| 1685-5MG | AM 404 (in Tocrisolve™ 100) | 5 mg | Tocris |
SCH-772984CAS号： 942183-80-4分子式： C33H33N9O2分子量： 587.67描述纯度储存/保存方法别名外观可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively. |
| 纯度 |
>98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 基本信息 | |
| 别名 |
SCH 772984; SCH772984
|
| 外观 |
Powder
|
| 可溶性/溶解性 |
DMSO ：10 mg/mL (17 mM) warmed
|
| 生物活性 | |
| 靶点 |
ERK2 ,ERK1
|
| In vitro(体外研究) |
SCH772984 is a novel, selective and ATP competitive inhibitor of ERK1/2. SCH772984 inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner. SCH772984 also inhibits phosphorylation of residues in the activationloop of ERK itself. SCH772984 demonstrates EC50 values
|
| In vivo(体内研究) |
SCH772984 induces tumor regressions in xenograft models at tolerated doses. SCH772984 effectively inhibites MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models.
|
分子结构图
ML-261CAS号： 902523-58-4分子式： C20H23ClN2O3S分子量： 406.9描述纯度储存/保存方法别名参考文献
| 产品描述 | |
| 描述 |
Lipid droplets are a fundamental component of intracellular lipid homeostasis in all cell types and they can provide a rapidly mobilized lipid source for many important biological processes such as membrane trafficking and cell signaling.1,2 Non-alcoholic fatty liver disease is associated with an increase in the number and size of lipid droplets found in hepatocytes and can lead to inflammatory complications including steatohepatitis and liver dysfunction.3 ML-261 is a thienopyrrole-5-caboxamide compound that inhibits hepatic lipid droplet formation (IC50 = 69.7 nM in mouse AML-12 hepatocytes).4
|
| 纯度 |
≥98%
|
| 储存/保存方法 |
Store at -20℃
|
| 基本信息 | |
| 别名 |
CID-9550710;
|
| 参考文献 | |
| 参考文献 |
1.Kadereit, B.,Kumar, P.,Wang, W.J., et al. Evolutionarily conserved gene family important for fat storage. Proceedings of the National Academy of Sciences of the United States of America 105(1), 94-99 (2008).
2.Martin, S. and Parton, R.G. Lipid droplets: a unified view of a dynamic organelle. Nature Reviews.Molecular Cell Biology 7, 373-378 (2006). 3.Burt, A.D. Steatosis and steatohepatitis. Current Diagnostic Pathology 7, 141-147 (2001). 4.Zou, J.,Ganji, S.,Pass, I., et al. Potent inhibitors of lipid droplet formation. 1-17 (2011). |
分子结构图
Rabbit anti-VPAC2 Monoclonal Antibody(JRMR-238)别名宿主反应种属应用纯化方法类型克隆号同种型储存/保存方法背景说明细胞定位UniProt
| 概述 | |
| 别名 |
VPAC2 抗体;PACAP-R3; VPAC2; FLJ16511
|
| 宿主 |
Rabbit
|
| 反应种属 |
Human, Mouse, Rat
|
| 应用 |
IHC-P:1:200-1:1000; ICC/IF:1:50;
|
| 性能 | |
| 纯化方法 |
Protein A
|
| 类型 |
Monoclonal Antibody
|
| 克隆号 |
JRMR-238
|
| 同种型 |
IgG
|
| 储存/保存方法 |
储存温度：-20℃, 避免反复冻融
|
| 靶标 | |
| 背景说明 |
人类VIPR2（血管活性肠多肽受体2），又称VPAC2，是一种60-70 kDa的七跨膜糖蛋白受体，属于G蛋白耦合受体2系列蛋白质。在其第一个细胞外区域激素受体域（aa 49-114）上包含成熟的链，其中具有三个N链接的糖基化位点和一个”西莉亚靶向信号”，由和Arg-Asp-Tyr-Arg序列组成。人类VIPR2与小鼠和大鼠VIPR2具有较高的同源性。VIPR2主要在骨骼肌、CD4+T细胞、平滑肌细胞、状树突细胞、肝前体细胞、单细胞、合成细胞和选择神经元中表达。VIPR2 与CAMP 介导的信号转导通路耦合，并结合 VIP 和垂体腺酸酶激活多肽 （PACAP）。
|
| 细胞定位 |
细胞膜
|
| UniProt |
P41587
|
GAD65 (206-220)分子量： 1757.1描述序列纯度储存/保存方法别名参考文献
| 产品描述 | |
| 描述 |
A Glutamic acid decarboxylase 2 (GAD2) peptide corresponding to residues 206 to 220 of GAD65. GAD2 is presented to T cells in association with I-Ag7 MHC class II molecules. This peptide was also used as a part of Ig chimeras to test whether IL-10 inter |
| 序列 |
H – Thr – Tyr – Glu – Ile – Ala – Pro – Val – Phe – Val – Leu – Leu – Glu – Tyr – Val – Thr – OH
|
| 纯度 |
≥ 95%
|
| 储存/保存方法 |
-20°C
|
| 基本信息 | |
| 别名 |
TYEIAPVFVLLEYVT
|
| 参考文献 | |
| 参考文献 |
Gregg, R. et al. J. Immunol. 174, 662 (2005).
|